Cullinan Oncology Inc. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.
The company stated in the following report that they exploit animals for product testing.
“CLN-617 is a multi-functional cytokine therapeutic candidate designed to exploit the synergistic activities of IL-2 and IL-12 in a single therapeutic agent. We have validated the bioactivity of several murine surrogate designs and demonstrated antitumor activity in in vivo animal models. We intend to submit an IND for CLN-617 in 2022.” (Page 154) Read the full document
Cullinan Oncology, Inc., formerly Cullinan Management, Inc. is a biopharmaceutical company. The Company is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients.
Company Website: http://www.cullinanoncology.com